Acquisition by Mollica Joseph A of 138 shares of Altamira Therapeutics subject to Rule 16b-3

CYTO Stock  USD 0.44  0.03  5.53%   
About 61% of Altamira Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Altamira Therapeutics suggests that many traders are alarmed. Altamira Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Altamira Therapeutics. Many technical investors use Altamira Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Altamira Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Altamira insider trading alert for acquisition of common stock, $0.01 par value per share by Mollica Joseph A, Director, on 6th of December 2024. This event was filed by Altamira Therapeutics with SEC on 2005-07-06. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Altamira Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Altamira Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Altamira Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Altamira Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Altamira Therapeutics Fundamental Analysis

We analyze Altamira Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altamira Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altamira Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Altamira Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Altamira Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altamira Therapeutics stock to make a market-neutral strategy. Peer analysis of Altamira Therapeutics could also be used in its relative valuation, which is a method of valuing Altamira Therapeutics by comparing valuation metrics with similar companies.
When determining whether Altamira Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Altamira Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Altamira Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Altamira Therapeutics Stock:
Check out Altamira Therapeutics Hype Analysis, Altamira Therapeutics Correlation and Altamira Therapeutics Performance.
To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.82
Revenue Per Share
0.917
Quarterly Revenue Growth
(0.64)
Return On Assets
(0.57)
Return On Equity
(3.69)
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.